Current Healthcare Systems Non-Sustainable
Healthcare systems worldwide are facing a crisis of sustainability.
Due to population aging and lifestyle factors, chronic diseases are on the rise and with that, escalating costs of treatment.
It is well recognized by governments and health providers that we must find a better approach to managing disease.
Recent advances in the understanding of the human genome and integration of genomic technologies into medical practice
will provide the necessary solutions for the sustainability of modern and efficient healthcare. GenomeDx Biosciences in
collaboration with leading health care researchers and practioners has developed unique approaches and solutions for the accurate diagnosis and prognosis of chronic diseases such as cancer.
Driving Personalized Medicine
One of society’s great challenges is to advance cancer patient care while mitigating its rapidly rising cost.
Today, when cancer care costs amount to tens of thousands of dollars per treatment course but do not guarantee
successful outcomes or worse yet, where many patients are unnecessarily over-treated, the medical system is faced with
a crisis of sustainability and effective use of healthcare resources. Genomic information when utilized appropriately by
healthcare professionals has the capacity to fundamentally alter the manner in which cancer is treated and managed
for the betterment of both the individual patient and the healthcare system as a whole. GenomeDx uses the genomic
information that lies within every individual to develop and deliver medical testing and clinical support tools for
personalized oncology. GenomeDx is driving a patient-centric approach initially in the oncology sector, by inviting
and enabling its primary customers - cancer care practitioners and providers - to collaborate on a massive scale to solve
these major medical, social and economic problems.
GenomeDx Technology
The company has developed standard operating protocols for processing patient samples from a wide variety of tumor types.
These methods are readily applicable to many other kinds of routine patient samples in cancer medicine
(e.g., formalin-fixed paraffin embedded biopsies). The company currently uses industry leading Affymetrix microarrays
to perform unbiased whole-genome expression profiling on formalin-fixed paraffin embedded samples with over 1
million data points in the genome largely ignored by competing efforts. The company’s proven technology generates
high-resolution data on archived samples as old as 20 years enabling retrospective analysis of patient groups with
annotated medical history and known clinical outcomes. GenomeDx differentiates itself by generating whole-genome
data on each patient regardless of the tumor type or disease condition and uses sophisticated bioinformatics and
analytic tools to provide medical professionals with on-demand information they require.
